文献速递临床试验与 GCP真实世界研究与卫生经济

以患者为中心的数字依从性技术对结核病治疗结局的评估:实用随机对照试验

Evaluation of patient centred digital adherence technology for tuberculosis treatment outcomes: pragmatic randomised controlled trial.
PubMed 文献 · BMJ · 2026-08-06

该实用随机对照试验在阿根廷布宜诺斯艾利斯4家公立医院纳入555例新诊断药物敏感结核病患者,随机分为标准治疗组(n=278)和标准治疗联合TB-TST数字依从性工具组(n=277)。意向性分析显示干预组治疗成功率82%,对照组74%,风险差7.1%(95%CI 1.1%~14.1%),风险比1.10(1.00~1.20;P=0.04);干预组失访率更低(17% vs 24%;RR 0.70,0.50~0.98;P=0.04)。

要点

  • TB-TST数字依从性工具可提高药物敏感结核病治疗成功率并降低失访。
  • 女性和35岁以下参与者获益更明显。
  • 该工具在低资源环境中可行且有效。

核心结论

  • 多层面交互式数字依从性工具改善了结核病治疗结局,尤其在年轻参与者和女性中。

研究设计与样本

  • 实用、两臂、平行随机对照试验,在阿根廷布宜诺斯艾利斯4家公立参考医院开展。

主要发现

  • 意向性分析中干预组治疗成功208/255(82%),对照组201/270(74%)。
  • 风险差7.1%(95%CI 1.1%~14.1%),风险比1.10(1.00~1.20;P=0.04)。
  • 干预组失访率17%,对照组24%;风险比0.70(0.50~0.98;P=0.04)。
  • 女性和35岁以下参与者中观察到更大获益。

临床怎么用

  • 在低资源环境中可考虑使用该数字依从性工具支持结核病治疗依从性。
  • 对女性和年轻患者可能优先考虑使用该工具。

局限性

  • 未来需评估应用参与度、背景因素(如COVID-19大流行)、成本效果以及在结核病以外慢性病管理中的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of Tuberculosis Treatment Support Tools (TB-TST), a patient centred digital adherence technology, in improving treatment outcomes among individuals with drug susceptible tuberculosis in Argentina. DESIGN: Pragmatic, two arm, parallel randomised controlled trial. SETTING: Four public reference hospitals in Buenos Aires, Argentina. PARTICIPANTS: 555 patients aged ≥16 years with newly diagnosed drug susceptible tuberculosis, recruited between November 2020 and July 2023, randomised to standard of care (n=278) or standard of care plus TB-TST (n=277). INTERVENTION: A mobile application that enabled daily adherence reporting, bidirectional messaging with treatment supporters, educational content, and a weekly urine based isoniazid test for verification of adherence. Participants and care givers were aware of their group assignment, but data collectors and data analysts were masked. MAIN OUTCOME MEASURES: The primary outcome was treatment success (cure or treatment completion). Secondary outcomes included loss to follow-up. Analyses used intention-to-treat and per protocol approaches. RESULTS: 525 participants (94.6% of the enrolled population) were included in the analysis after exclusion of 30 individuals who deviated from the protocol. In the intention-to-treat analysis, treatment success was higher in the intervention group (208/255; 82%) than in the control group (201/270; 74%). The risk difference was 7.1% (95% confidence interval 1.1% to 14.1%), and the risk ratio was 1.10 (1.00 to 1.20; P=0.04). Loss to follow-up was lower in the intervention group (17% v 24%; risk ratio 0.70, 0.50 to 0.98; P=0.04). Greater benefit was observed among female participants and those aged under 35 years. CONCLUSIONS: A multifaceted, interactive digital adherence tool improved tuberculosis treatment outcomes, particularly among younger participants and women, showing feasibility and effectiveness in supporting adherence to tuberculosis treatment in low resource settings. Future research should evaluate the impact of app engagement, context factors such as the covid-19 pandemic, cost effectiveness, and use of the tool beyond tuberculosis in the management of chronic diseases. AI powered features and integrated mental health support may enhance the scalability and personalisation of care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04221789; International Registered Report Identifier DERR1-10.2196/28094.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Rubinstein F, Moraes Morelli D, Palma I, et al. Evaluation of patient centred digital adherence technology for tuberculosis treatment outcomes: pragmatic randomised controlled trial. BMJ. 2026. PMID: 42562413. doi:10.1136/bmj-2026-100195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。